Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.

Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.